EPRX · Eupraxia Pharmaceuticals Inc. · Documents

Upraxia Pharmaceuticals plans an early December Phase IIb interim readout for EP-104GI in eosinophilic esophagitis. Dose-escalation data showed 64% of patients in clinical remission at 52 weeks, while FACE-2B will extend follow-up beyond 52 weeks.

Eupraxia Pharmaceuticals announced a virtual Analyst Day on November 13, 2026 to discuss EP-104GI for Eosinophilic Esophagitis; EP-104GI is currently in a Phase 1b/2 trial.

Eupraxia reached enrollment of 120 patients in the blinded Phase 2b portion of the RESOLVE trial; over 3,000 injections have been administered with no treatment-related SAEs, and interim analysis is on track for December 2026.

Eupraxia Pharmaceuticals announced three RESOLVE trial abstracts accepted for ACG 2026 and UEG Week 2026, covering EP-104GI effects on dysphagia and histopathology. Its Phase 2b is recruiting 120mg and 160mg doses, with interim data expected in December 2026.

Eupraxia Pharmaceuticals reported 52-week RESOLVE data showing 64% (9/14) of patients in clinical remission after one EP-104GI dose, 66% (2/3) in the highest-dose cohort, and Phase 2b interim data expected in December 2026.

• Non-issuer's submission to jurisdiction and appointment of agent 4
• Shelf prospectus (NI 44-102) 1

• Shelf prospectus (NI 44-102) 3
• Non-issuer's submission to jurisdiction and appointment of agent 3
• Consent letter of issuer's legal counsel 1
• Final short form prospectus 1
• Other offering documents 3